X4 Pharmaceuticals Inc Dossier - Source-backed chat

X4 Pharmaceuticals Inc

XFORNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.58

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $2.90Price as of 30 Sep 2026

Data confidenceNot applicable

Market Cap $287.5M

Enterprise Value $147.1M

Shares Outstanding 94.3M diluted

Next Earnings Date5 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

X4 Pharmaceuticals is successfully transitioning from a clinical-stage biotech to a commercial-stage rare disease leader. The investment thesis is anchored by the commercial launch of XOLREMDI (mavorixafor) for WHIM syndrome, which recently secured European Commission approval in April 2026, and the high-potential expansion into chronic neutropenic disorders (CND). With a robust cash runway extending through 2028 following strategic restructurings and successful financings, X4 is well-positioned to execute on its upcoming late-2026 Phase 3 4WARD trial readout, representing a major valuation inflection point.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets5 analysts · as of 18 Aug 2026

Low · most bearish analyst$10.00

Mean target$11.60

High · most bullish analyst$13.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$1.50

The bear case centers on potential clinical or regulatory setbacks. If the Phase 3 4WARD trial fails to meet its primary endpoints (ANC response or infection rate reduction) or shows unexpected safety signals, the expansion into chronic neutropenia would be severely compromised. Additionally, slower-than-expected commercial adoption of XOLREMDI in WHIM syndrome would accelerate cash burn, forcing highly dilutive capital raises before the end of the current runway in 2028.

Base CaseCentral scenario

$11.60

Matches the consensus mean

The base case assumes steady, moderate commercial growth of XOLREMDI in the U.S. and a successful European launch with Norgine. The pivotal 4WARD Phase 3 trial completes enrollment in Q3 2026 and delivers positive top-line results in late 2026, in line with strong historical Phase 2 data. The company's cash runway remains secure through 2028, allowing it to prepare regulatory submissions for chronic neutropenia without near-term dilutive financing overhang.

Bull CaseUpside scenario

$12.00

The bull case is driven by rapid commercial uptake of XOLREMDI in both the U.S. and Europe (via partner Norgine), triggering substantial milestone payments. Furthermore, positive top-line Phase 3 4WARD data in late 2026 would de-risk mavorixafor's expansion into the chronic neutropenia market, which represents a significantly larger addressable patient population (~15,000 in the U.S.) than WHIM syndrome, driving substantial long-term revenue growth and potential analyst price targets up to $12.00.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

De-risked mechanism of action with XOLREMDI already approved by the FDA and European Commission for WHIM syndrome.
Large addressable market expansion opportunity in chronic neutropenia (~15,000 patients in the U.S.) currently served only by injectable G-CSF.
Strong balance sheet with $233.7 million in cash as of March 31, 2026, providing runway through 2028.
Strategic ex-U.S. commercial partnership with Norgine, offering up to €226 million in milestones plus royalties.

Key Investment Risks

Clinical trial risk associated with the ongoing Phase 3 4WARD study in chronic neutropenia.
Commercial execution risk in the ultra-rare WHIM syndrome market, which requires intensive patient identification efforts.
Dependence on a single primary asset (mavorixafor) for near-to-mid-term value creation.

Thesis Invalidation Triggers

Failure of the Phase 3 4WARD trial to achieve statistical significance on its primary endpoints.
A material downward revision of the cash runway projection due to unexpected commercialization costs or clinical delays.
Regulatory rejection or significant delays of mavorixafor filings in major international jurisdictions.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.